581 related articles for article (PubMed ID: 20102127)
1. Evaluating the bioavailability and bioequivalence of generic medications.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127
[TBL] [Abstract][Full Text] [Related]
2. What makes a generic medication generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
[TBL] [Abstract][Full Text] [Related]
3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
4. When is a "generic" medication not really a generic?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Feb; 48(2):13-6. PubMed ID: 20166651
[TBL] [Abstract][Full Text] [Related]
5. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
6. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
7. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Bialer M; Midha KK
Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
[TBL] [Abstract][Full Text] [Related]
8. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
Chow SC; Hsieh TC; Chi E; Yang J
J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
[TBL] [Abstract][Full Text] [Related]
9. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
Borgheini G
Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
[TBL] [Abstract][Full Text] [Related]
10. Generic substitution: issues for problematic drugs.
Henderson JD; Esham RH
South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935
[TBL] [Abstract][Full Text] [Related]
11. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
Knoben JE; Scott GR; Tonelli RJ
Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
[TBL] [Abstract][Full Text] [Related]
12. Critical therapeutic categories: a contraindication to generic substitution?
Colaizzi JL; Lowenthal DT
Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
[TBL] [Abstract][Full Text] [Related]
13. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
14. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of generic agents in psychopharmacologic treatment.
Kumet R; Gelenberg AJ
Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794
[TBL] [Abstract][Full Text] [Related]
16. Modeling and simulation of biopharmaceutical performance.
Zhang X; Lionberger RA
Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
[TBL] [Abstract][Full Text] [Related]
17. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
18. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the bioavailability/bioequivalence controversy.
Gottschalk LA
J Clin Psychiatry; 1986 Sep; 47 Suppl():3-5. PubMed ID: 3528133
[TBL] [Abstract][Full Text] [Related]
20. Requirements for submission of bioequivalence data; final rule. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]